Tag Archives: CVS

Jose Arango, New Jersey GOP Leader, Compares Female Lt. Gov. Candidate To His Secretary

By The Huffington Post News Editors

A county Republican Party chairman in New Jersey had some harsh words this week for Hispanic labor leader Milly Silva, the newly tapped running mate of the state’s Democratic candidate for governor.

“Poor thing,” Jose Arango, the chairman, said of Silva, who is the executive vice president of labor union SEIU 1199. “It’s like picking my secretary. She’s a very nice person. The union likes her, but even in the union she’s vice president. She hasn’t been a committeewoman.”

Arango added, “It’s like the guy in CVS with no expertise who suddenly gets promoted to pharmacist. It’s like the guy saying, ‘I work at CVS, I can be the pharmacist.'”

Read More…
More on Chris Christie

…read more

Source: FULL ARTICLE at Huffington Post

Rolling Stone And The Bomber Suspect: What Media Coverage Has Missed

By Cheryl Conner, Contributor

I swore I wasn’t going to weigh in on this topic. But longtime online marketing expert Barbara Ling gave me several good reasons to reconsider (one of them being that she offered me an image that didn’t further perpetuate the suspect’s controversial face.)   I’ve known Barbara since the days I used to pitch her as a press authority on Internet recruiting back in the days my agency represented FlipDog (later acquired by Monster.com). She’s a 17-year “soloprenuer” who, in addition to Internet recruiting, specializes in what she refers to as “in-the-trenches” online marketing via social media. A mother of four, she focuses on demystifying social media for emerging businesses. Barbara and I share a love of marketing and of entrepreneurs. We have no business relationship together, but as time progresses, perhaps that will change. Barbara pointed out to me that in the fallout over the July 17 Rolling Stone Magazine that unless you’ve been living under a stone, you realize features a photo of the Boston Bombing Suspect Dzhokhar Tsamaev. The consumer world reacted, primarily with outrage. CVS and Walgreens both refused the carry the issue, as Forbes’ Matthew Herper reported last week. But here’s the surprise Barbara brought to my attention: Within 24 hours, a Facebook site emerged with the headline “Boycott Rolling Stone Magazine For Their Latest Cover.” The message on the page: “Rolling Stone announced its new cover today, featuring the Boston Bomber.  This is unacceptable and a slap in the face for those he killed and maimed.” The site garnered more than 100,000 “Likes” in its first 24 hours. That’s the equivalent of 4169 “likes” an hour, 69 “Likes” a minute and a “like” every 6/7 of a second. So what’s even bigger about this? It’s the very structure of Facebook sharing that makes such a rabid and viral uprising possible and actually fuels its growth. When a Facebook user “Likes” a page, the “Like” generally shows up (unless you’ve active prohibited it) in that individual’s feed, allowing everyone in his or her network to see it as well. Fueling the viral mania fire even further, many media outlets and Facebook users also “hashtagged” their posts with the cryptic message of #Boycott and #RollingStone, helping to spur even more sharing via Facebook’s new Open Graph Search. This phenomena results in more users and more Facebook viewers being polarized to one side or the other. Grass roots Facebook campaigns are nothing new. In May, Women, Action and the Media was able to persuade advertisers to pull their ads in protest of “rape joke” pages on Facebook. In the face of the mountain of infuriated users, Facebook re-thought its position and the pages came down. Once a controversial passion has been ignited on Facebook to this extent it becomes virtually unstoppable, Barbara says, but here is the powerful takeaway she urges small business to note:  The Facebook community can make or break a brand’s appeal. Therefore, businesses must be highly mindful to ensure their social media interactions increase, …read more

Source: FULL ARTICLE at Forbes Latest

Retailers vow not to sell Rolling Stone issue as critics blast decision to put accused Boston bomber on cover

At least five retailers with deep New England ties will not sell the Rolling Stone magazine featuring an unsmiling, scruffy Boston Marathon bombing suspect Dzhokhar Tsarnaev on its cover.

The picture, which accompanies a story titled “Jahar’s World,” shows the 19-year-old accused murderer with his long, curly hair tousled, reminiscent of the magazine’s iconic shots of rock ‘n’ roll royalty like The Doors’ Jim Morrison and Bob Dylan.

The issue, which hits newsstands Friday, depicts Tsarnaev above a boldface headline, “The Bomber.” The story, which features interviews from childhood friends, teachers and law enforcement agents, promises to reveal how a “popular, promising student was failed by his family, fell into radical Islam, and became a monster.”

Multiple retailers, including CVS and Walgreens, have decided not to carry the issue in their stores.

“CVS/pharmacy has decided not to sell the current issue of Rolling Stone featuring a cover photo of the Boston Marathon bombing suspect,” the Rhode Island-based pharmacy chain said in a statement. “As a company with deep roots in New England and a strong presence in Boston, we believe this is the right decision out of respect for the victims of the attack and their loved ones.”

Other retailers who have said they will not carry the issue include Walgreens, Rite Aid, Stop & Shop, the grocery chain the Roche Bros and Tedeschi Food Shops, a Massachusetts-based convenience store chain.

Other critics of the cover, including Boston Mayor Tom Menino and Massachusetts Gov. Deval Patrick, struck fast, accusing the magazine of offering Tsarnaev “celebrity treatment” and calling the cover “ill-conceived, at best in a letter written by Menino to Rolling Stone publisher Jann Wenner.

“The survivors of the Boston attacks deserve Rolling Stone cover stories, though I no longer feel that Rolling Stone deserves them,” the letter concluded.

Rolling Stone, for its part, issued a statement Wednesday saying the story was part of its “long-standing commitment to serious and thoughtful” coverage of the most important current political and cultural issues.

“The fact that Dzhokhar Tsarnaev is young, and in the same age group as many of our readers, makes it all the more important for us to examine the complexities of this issue and gain a more complete understanding of how a tragedy like this happens,” the statement said.

Rolling Stone did not address whether the photo was edited or filtered in any way in a brief statement offering condolences to bombing survivors and the loved ones of the dead.

In a blog posting late Tuesday, Rolling Stone detailed “five revelations” in the story by contributing editor Janet Reitman, including Tsarnaev’s increasing devotion to Islam while still in high school, as well as his older brother Tamerlan Tsarnaev’s possible mental illness, which the boys’ mother decided would be better treated by Islam than by a psychiatrist.

“Around 2008, Jahar’s older brother Tamerlan confided to his mother that he felt like ‘two people’ were inside him,” the blog posting reads. “She confided this to a close friend who felt he might need a psychiatrist, but Zubeidat believed that religion would be the …read more

Source: FULL ARTICLE at Fox US News

Rolling Stone Cover With Dzhokhar Is Great

By John Johnson

Chances are you’ve heard about the decision by Rolling Stone to put Dzhokhar Tsarnaev on the cover . Critics have been in a rage all day, and stores including CVS say they won’t even stock it. It’s offensive, exploitative, and glorifies violence are the more common refrains. At Slate , Mark Joseph… …read more

Source: FULL ARTICLE at Newser – Home

Application packages

By pjeedu2247

Hello,

I just build an AIX 7.1 box. I’m trying to install the following packages:

BASH
APACHE
CVS
ZIP

I tired to download them searching on google, but unfortunately I dint find any packages concerned with aix7.1. I got stuck at this point and dont know where to download those packages and there dependencies.

Please guide me further.

Thank you.

…read more

Source: FULL ARTICLE at The UNIX and Linux Forums

Suit: Phrase mocking Asians on NJ CVS photo tix

A southern New Jersey woman of Korean descent is suing CVS Pharmacy, claiming a worker used a phrase mocking Asians to identify her on a receipt for photographs.

Attorney Susan Lask says Hyun Lee was picking up photos Feb. 7 at a CVS in Egg Harbor City when Lee noticed the phrase “Ching Chong Lee” on her ticket.

Lee says she had used her own name when she ordered the photos online. Lee says she complained to CVS customer relations and was told the worker would be “counseled and trained.”

CVS spokesman Mike DeAngelis says the company can’t comment on litigation but has a firm non-discrimination policy.

Lask is seeking $1 million is the discrimination lawsuit filed Tuesday in Camden.

She’s scheduled a news conference with her client in Belmar Thursday.

From: http://feeds.foxnews.com/~r/foxnews/national/~3/XqSPwb7wiqE/

Walgreens Stock Deserves a Spot in Your Portfolio

By Tamara Rutter, The Motley Fool

Filed under:

Walgreens  stock has been on a roll this year, with shares up more than 29% year-to-date . This is an impressive run for a company that’s still recovering from its breakup and make-up with pharmacy benefits manager Express Scripts . However, the rise of generics, international growth, and the aging population should also play to Walgreens’ favor in the year ahead.

Top dividend stock
In addition to these catalysts, Walgreens is also one of the better dividend stocks to own. Walgreens stock pays an attractive quarterly dividend, and has done so without interruption for more than 80 years. Additionally, the company has earned its title as a dividend aristocrat by increasing its payout for 37 consecutive years. The stock‘s current dividend yield of 2.3% looks even better if you consider that over the last five years Walgreens stock has achieved a compound annual growth rate of nearly 24%.

The company’s long history of payouts helped shareholders remain calm during a turbulent 2012. Most of the upset was related to the fact that Walgreens said goodbye to about $5 billion in annual sales when it lost Express Scripts‘ business. Because the drugstore chain would no longer fill prescriptions for patients in the Express Scripts network, it ultimately forced its customers into the arms of the competition.

Lessons learned
CVS Caremark
and Rite Aid benefited the most from Walgreen’s fallout with Express Scripts. This is because at the time, both CVS and Rite Aid still accepted Express Scripts plans. The rival pharmacy retailers launched aggressive advertising campaigns that specifically targeted Walgreens customers whom held Express Scripts insurance .

It took Walgreens and Express Scripts nearly seven months to work out their differences — costing Walgreens billions in lost sales. However, the two companies finally reached a new multiyear agreement during July of last year. Walgreens stock soared more than 10% last year on that news alone.

Around the same time, investors were also busy dissecting the company’s acquisition of Alliance Boots. If you remember, Walgreens agreed to pay $6.7 billion in cash and stock for a 45% stake in the European drugstore chain.

Fast-forward to 2013
Today, Walgreens is proving that its 2012 purchase of Alliance Boots was less of a knee-jerk reaction to its Express Scripts woes, and more of a long-term play for international growth. Together with Boots, Walgreens inked a 10-year deal with pharmaceutical distributor AmerisourceBergen . As part of the agreement, AmerisourceBergen is giving Walgreens and Alliance Boots the option to buy a minority position in the company or as much as 7% of AmerisourceBergen’s outstanding stock. Walgreens and Alliance Boots also received warrants exerciseable for a 16% equity position in AmerisourceBergen .

Both Walgreens stock and shares of AmerisourceBergen climbed higher last month when the partnership was announced. With AmerisourceBergen now handling Walgreen’s branded and generic drug distribution, Walgreens should see increased efficiencies in its global pharmaceutical supply chain. Moreover, this

From: http://www.dailyfinance.com/2013/04/11/walgreens-stock-deserves-a-spot-in-your-portfolio/

The U.S.' 10 Most Valuable Retail Brands of 2013

By Dan Dzombak, The Motley Fool

Filed under:

Recently, brand consultancy Interbrand came out with its report on the 50 most valuable U.S. retail brands of 2013. Read on to find out the top 10.

So how did Interbrand determine their value? In short, Interbrand looks at three key aspects. First is the financial performance of the branded products or services. Interbrand only considers companies with publicly available data that are creating economic value (meaning a positive EBITDA) and generating a minimum of 50% of their sales from their retail stores (this excludes Apple).

The other two aspects Interbrand considers are the role of the brand in the purchase decision process and the strength of the brand — meaning, “the ability of the brand to create loyalty and, therefore, to keep generating demand and profit into the future.”

Here are Interbrand’s 10 most valuable U.S. retail brands of 2013:

Rank

Company

Brand Value
(in billions)

Change From 2012

1

Wal-Mart

$141.0

1%

2

Target

$25.0

7%

3

Home Depot 

$22.9

4%

4

Amazon.com

$18.6

46%

5

CVS

$15.9

(8%)

6

Coach

$14.6

8%

7

Walgreen

$14.4

(4%)

8

Sam’s Club (a subsidiary of Wal-Mart)

$13.5

5%

9

eBay

$10.9

12%

10

Nordstrom

$10.1

7%

Source: Interbrand.

Wal-Mart is the most valuable retail brand in the U.S. by a factor of five. Remarkably, Wal-Mart subsidiary Sam’s Club is the eighth most valuable retail brand in the U.S. Wal-Mart established itself as the dominant low-cost retailer over decades by constantly improving on its processes and supply chain skills under the leadership of Sam Walton. While Sam is no longer with us, Wal-Mart continues to thrive and his family leadership continues today under Chairman S. Robson Walton.

Many people don’t realize the difference in size between Wal-Mart and other retailers. The company’s sales for the fiscal year ended Jan. 31, 2013, were $275 billion in the U.S. Compare that to the second most valuable retail brand in the U.S., Target , with sales of just $72 billion. Even Amazon.com , 2013’s fastest-growing major brand, only did $35 billion in sales in the U.S. in the past year.

Notably absent from the top 10 this year is Best Buy , which moved from fifth in 2012 to 13th in 2013 as the company’s brand value dropped 52% to $8 billion. The electronics retailer had a tough 2012 as shoppers treated its stores as showrooms and then used apps to buy goods cheaper online from Amazon and eBay. In the past, both online retailers benefited from not having to collect state sales taxes, but that advantage is slowly ending.

Best Buy is slowly turning things around this year. It announced in February a policy to match prices found online, and earlier this month that

From: http://www.dailyfinance.com/2013/04/11/the-us-10-most-valuable-retail-brands-of/

Rite Aid Earnings: An Early Look

By Dan Caplinger, The Motley Fool

Filed under:

Earnings season has begun, and on Thursday, Rite Aid will release its latest quarterly results. The key to making smart investment decisions on stocks reporting earnings is to anticipate how they’ll do before they announce results, leaving you fully prepared to respond quickly to whatever inevitable surprises arise. That way, you’ll be less likely to make an uninformed knee-jerk reaction to news that turns out to be exactly the wrong move.

Rite Aid has been the third wheel of the U.S. drugstore industry for a long time, as it has struggled to reach profitability even as its main rivals have seen substantial growth in sales and earnings over the years. Can Rite Aid ever recover? Let’s take an early look at what’s been happening with Rite Aid over the past quarter and what we’re likely to see in its quarterly report.

Stats on Rite Aid

Analyst EPS Estimate

($0.02)

Year-Ago EPS

($0.18)

Revenue Estimate

$6.45 billion

Change From Year-Ago Revenue

(9.8%)

Earnings Beats in Past 4 Quarters

3

Source: Yahoo! Finance.

Does Rite Aid have the right prescription for its business?
Analysts have had mixed views on Rite Aid‘s prospects over the past few months. They’ve cut their initial break-even estimates for the company’s most recent quarter to a loss of $0.02 per share, but they’ve also boosted fiscal 2014 earnings estimates to a profit of $0.03 per share. The stock has focused on the longer-term view, as Rite Aid‘s share price has jumped more than 30% since the beginning of the year.

For a while last year, it looked as if Rite Aid might finally be turning the corner after a long period of weakness. A dispute between rival Walgreen and pharmacy benefit manager Express Scripts led to an exodus of customers away from Walgreen, and Rite Aid appeared to capture its share of those seeking to have their prescriptions filled elsewhere.

Since then, though, Rite Aid has sunk back into old bad habits. In March, it announced a 2% drop in same-store sales, with a drop in pharmacy sales of 4.5% more than offsetting a nearly 4% increase in revenue from the front-end of its stores. Yet even that front-end strength came largely from Easter’s coming in March rather than April this year, suggesting that the retailer’s results were even weaker than reported. Meanwhile, Walgreen has seen same-store sales grow as its new loyalty program attempts to win back customers from Rite Aid and CVS Caremark .

Rite Aid has fought back, though, seeking to match up to Walgreen and CVS by remodeling its stores. But because it is already debt-ridden, Rite Aid can’t afford to do store remodeling at a very fast pace, with Fool contributor Adam Levine-Weinberg arguing that it could take a decade for the company to finish all of its renovations.

In Rite Aid‘s quarterly report, watch for …read more

Source: FULL ARTICLE at DailyFinance

Why Your Next Doctor's Visit May Be a Trip to the Pharmacy

By Tamara Rutter, The Motley Fool

Filed under:

Next time you make a doctor’s appointment, it may be with your local drugstore. As if Obamacare hasn’t caused enough of a shakeup in health care, convenient care clinics across the U.S. now promise to diagnose, treat, and monitor patients with chronic illnesses. In fact, drugstore companies including Walgreen and CVS Caremark are at the forefront of this trend.

This could further disrupt an already rattled health care industry — particularly because the services provided by drugstore clinics are often more convenient and affordable than a doctor’s visit.

A dose of convenience
Walgreens is aggressively expanding the scope of services offered at its in-store Take Care Clinics. Last week, the country’s largest drugstore chain said it would begin treating patients with chronic conditions including asthma, diabetes, and high blood pressure.

This is a smart move for Walgreen at a time when the U.S. is facing a shortage of doctors. Not to mention, Obamacare will have a big impact on the health care industry next year as millions of previously uninsured people will gain coverage.

Meanwhile, rival pharmacy chain CVS is also putting a greater emphasis on treating patients at its walk-in clinics. CVS, which currently operates around 640 MinuteClinics, expects to have as many as 800 MinuteClinics by year’s end. While Walgreen’s footprint is a bit smaller with just 372 clinics now in operation, the company plans to open more locations in the year ahead. Of course, there’s a catch.

The doctor won’t see you
One thing to keep in mind are that these convenient care clinics, as they’re called, are not staffed by doctors but instead manned by nurse practitioners and physician assistants. While this may deter some customers, there’s something to be said about the flexibility of care clinics — most of which, are open extended hours and weekends.

With chronic care accounting for about three-quarters of health care spending, Walgreen’s push into this niche market should be a profit driver for the company down the road. It may even help Walgreen recover some of the customers it lost last year after the fallout with pharmacy benefits manager  Express Scripts .

Express Scripts, which provides a variety of pharmacy services including patient care and benefit management care, contributed about $5 billion in annual sales for Walgreen. However, when Walgreen dropped its contract with Express Scripts, it saw that revenue disappear along with tens of thousands of customers in the Express Scripts network. Fortunately, Walgreen settled the dispute with Express Scripts last year and inked a new multiyear deal with the company. Still, it’s been a slow climb for Walgreen as the pharmacy chain attempts to win back lost customers.

Moreover, by expanding the scope of services offered in its Take Care Clinics, Walgreen could see some of these lost customers return to its pharmacies. Going forward, Walgreen’s investment in its in-store clinics should start to pay off as more people ditch the doctor’s office for convenient …read more

Source: FULL ARTICLE at DailyFinance

Rite Aid Keeps Falling Behind

By Adam Levine-Weinberg, The Motley Fool

Filed under:

On Thursday morning, Rite Aid reported another month of lackluster sales results. For March, same-store sales were down 2%, whereas top competitor Walgreen reported a 0.7% increase in comparable-store sales. (The third pharmacy giant, CVS Caremark , does not report monthly sales.) Walgreen is continuing to recover strongly from last year’s dispute with Express Scripts , and the company appears to be winning market share back from Rite Aid. As a result, I expect Rite Aid‘s recent return to profitability to prove short-lived.

The details
Rite Aid‘s sales decline last month was comprised of a 3.8% increase in front-end sales and a 4.5% decrease in pharmacy same-store sales. Much of the decline can be explained by the introduction of various new generic drugs in the past year; generics are cheaper than brand-name drugs, but carry higher margins for pharmacies. It is perhaps more meaningful to look at prescription count, which does not differentiate between brand-name and generic drugs. On that basis, Rite Aid reported a modest 0.3% increase over the prior year.

On the other hand, Rite Aid estimated that front-end comparable-store sales benefited by 300 basis points due to the calendar shift of Easter into March. Stripping out all of the moving parts, it appears that Rite Aid‘s core sales growth is less than 1%, well below the pace seen for much of the last year.

Competition heats up
Much of Rite Aid‘s improved performance last year was a direct result of the commercial dispute between Walgreen and Express Scripts, which forced Express Scripts customers to fill their prescriptions elsewhere. While it is difficult to quantify the benefit seen by Rite Aid (and other Walgreen competitors), Rite Aid‘s management has admitted that pharmacy sales were boosted by the dispute last year. However, as of Sept. 15, 2012, Walgreen’s stores began to accept Express Scripts prescriptions again, and the company has a made a strong push since then to regain lost customers.

Whereas Rite Aid‘s prescription count in comparable stores increased by just 0.3% last month, Walgreen’s stores saw a 4% increase. Walgreen’s management also commented that “the percentage of former Express Scripts customers returning to its pharmacies continued to increase in March.”

Looking forward
Going forward, Rite Aid will continue to be squeezed by its two larger competitors, Walgreen and CVS. Now that Express Scripts customers are starting to return to Walgreen’s stores, Rite Aid is experiencing anemic sales growth. Furthermore, Walgreen and CVS are both expanding, while Rite Aid is gradually shrinking its store base. This trend will give Rite Aid‘s competitors even more economies of scale, while new CVS and Walgreen’s stores will likely target current Rite Aid customers.

Rite Aid stock is too speculative to recommend for most investors at this point in time. While Rite Aid‘s enterprise value of $8 billion is significantly below that of Walgreen ($49 billion) the lower valuation is fully justified by the company’s weak profitability. Rite Aid continues to face …read more

Source: FULL ARTICLE at DailyFinance

Generic Drugs Leave Rite Aid Feeling Sick

By Travis Hoium, The Motley Fool

Filed under:

Generic drugs are good for consumers’ wallets, but they aren’t good for many other players in the medical industry. Pharmaceutical companies that spend billions of dollars to develop brand name drugs feel the pinch when patents run out, and generics flood the market. Apparently, so do drug stores.

Rite Aid said today that same store sales fell 2% in March from a year earlier, driven by a decline in drug sales. Sales in the pharmacy, which accounts for 67.6% of overall revenue at Rite Aid, fell 4.5%, despite prescriptions rising slightly. This means that lower cost drugs, particularly in the form of generics, have taken a bite out of sales for Rite Aid.

The small silver lining is that the rest of the store is doing quite well. Front-end same-store sales, which is everything outside of the pharmacy, rose 3.8%, helped by a boost in Easter sales.

An industry trend takes hold
This is going to be a challenge for the industry going forward, and will also impact Walgreen’s and CVS . Walgreens reported a 0.7% rise in same-store sales for March, which was below expectations, showing similar trends as Rite Aid‘s. The company’s same-store pharmacy sales fell 1.5%, not as bad as Rite Aid, but still not a strong sign for the drug business.  

CVS doesn’t give the same-store sales data like Rite Aid and Walgreen’s but we can assume the trend of more generics and lower pharmacy sales will hold true.

Investors should be careful buying into the declining sales trends at all three companies. As health-care costs have risen, there has been pressure on all parts of the industry to cut costs, and that includes drug stores. That wouldn’t be a problem if the stocks were a screaming value, but Walgreen’s and CVS both have P/E ratios above 18, which is expensive considering sales trends, and Rite Aid is a risky turnaround story. That’s too much for this Fool to pay to get into the drug business.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies, and stick with them for the long term. The Motley Fool’s free report, “3 Stocks That Will Help You Retire Rich,” names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

The article Generic Drugs Leave Rite Aid Feeling Sick originally appeared on Fool.com.

Fool contributor Travis Hoium has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a …read more

Source: FULL ARTICLE at DailyFinance

Walgreen Clinics Target Chronic Illnesses in Care Expansion

By The Associated Press

Filed under: , , ,

Kevork Djansezian/Getty Images

By TOM MURPHY

Walgreen has expanded the reach of its drugstore clinics beyond treating ankle sprains and sinus infections to handling chronic diseases such as diabetes, asthma and high blood pressure.

Walgreen Co. (WAG), based in Deerfield, Ill., said Thursday that most of its 370 in-store Take Care Clinics now will diagnosis, treat and monitor patients with some chronic conditions that are typically handled by doctors.

Drugstore clinics, which are run by nurse practitioners or physician assistants, have grown popular in recent years as a convenient way for patients to get immunizations, physicals and treatment for relatively minor illnesses when their regular doctor is unavailable. But the clinics have been broadening their scope of care: Walgreen’s decision follows a move by CVS Caremark Corp. (CVS) a few years ago to handle chronic conditions at most of its 640 MinuteClinics.

Drugstores say they don’t aim to replace doctors, but rather to provide more people with access to health care and work with physicians as part of a team treating patients. But the move to provide more complex care has drawn concern from doctors who say that can disrupt their relationships with patients and lead to fragmented care.

Sponsored Linksadsonar_placementId=1505951;adsonar_pid=1990767;adsonar_ps=-1;adsonar_zw=242;adsonar_zh=252;adsonar_jv=’ads.tw.adsonar.com’;

Dr. Jeffrey J. Cain is president of the American Academy of Family Physicians, one of the nation’s largest medical organizations. He said doctors know their patients, and that makes them better suited for doing things like helping a patient with diabetes develop an exercise plan or learn how to eat better.

He also said that transferring records or test results between health care providers can be difficult if computer systems don’t communicate well. That can lead to test duplications.

“It’s not about telling somebody what they have to do, it’s helping them make choices in their life to move toward a healthier lifestyle,” he said.

Dr. Alan E. London, chief medical officer for the Take Care Clinics, said that the clinics can help coordinate a patient’s care. If a patient has a doctor and a treatment plan for a condition such as high cholesterol, the patient can use the clinics for blood tests and then have the results sent back to the doctor.

But nearly half of the patients who receive treatment at Walgreen clinics don’t have a primary care doctor, London said. In those cases, the clinics will diagnose a chronic illness, get the patient started on some medication and then help them connect with a doctor.

“We’re filling a niche for patients who need access,” London said. “When we uncover gaps in care and we’re capable of closing those gaps, it’s the right thing to do.”

%Gallery-184688%

Permalink | <a target=_blank href="http://www.dailyfinance.com/forward/20529868/" title="Send this …read more

Source: FULL ARTICLE at DailyFinance

Why CVS Charges $133 More Than Costco for Generic Lipitor

By CNNMoney

Filed under: , , , ,

Jb Reed, Bloomberg via Getty Images

By Emily Jane Fox

CVS (CVS) charges $150 for a monthly prescription of the generic version of the cholesterol drug Lipitor. The same drug goes for $17 at Costco.

That’s according to a recent Consumer Reports nationwide survey that sent secret shoppers to 200 pharmacies that carry five blockbuster drugs: Lipitor, Lexapro, Plavix, Actos and Singulair, all of which lost their patents in the last two years.

Shoppers found they could be paying as much as $749, or 447%, more for a generic prescription drug in one year at the highest-priced pharmacy, compared with the lowest.

The priciest places to pick up these prescriptions were CVS, Target (TGT) and Rite Aid (RAD). The least expensive were Costco (COST) and Sam’s Club, while Walmart (WMT), and Walgreen’s (WAG) fell in the middle.

So what’s behind the huge discrepancy?

Lisa Gill, a Consumer Reports editor who focuses on prescription drugs, said the difference stems primarily from what sells at the stores.

“At places like CVS or Rite Aid, the pharmacy is their major source of revenue and profit,” she said. “Costco and Sam’s Club are using the low drug prices to pull people in stores who will spend money on other things.”

Sponsored Linksadsonar_placementId=1505951;adsonar_pid=1990767;adsonar_ps=-1;adsonar_zw=242;adsonar_zh=252;adsonar_jv=’ads.tw.adsonar.com’;

Consumers are often willing to pay higher prices at a drug store because many of them are conveniently located, open 24 hours a day and have drive-through windows, according to Gill.

But for most people, it can be worth the extra hassle. This is especially true for those who take medication long-term, since they will get better deals at the warehouse clubs, or big box stores, Gill said.

Carolyn Castel, a spokeswoman for CVS, said that pricing surveys like this are too small to draw “meaningful conclusions about which pharmacies offer the best overall value.” She also noted that they don’t take into account the discount and third-party insurance programs that pharmacies use to lower prices.

A Target spokeswoman said it offers a number of ways for customers to save on drug prices, like rewards and discount programs.

Consumer Reports‘ Gill said these programs are helpful, but they’re not doing enough to lower costs.

It’s no secret that the cost of drugs can be prohibitive, especially at a time when incomes are stagnating. Consumer Reports found in a separate national telephone survey that Americans who regularly took prescription drugs, spent $758 out of pocket in 2012, or 12% more than the previous year.

Gill said that one way for people to save is by refilling prescriptions every 90 days instead of each month, since most pharmacies provide discounts on three-month supplies.

To get the best price, she said, people …read more
Source: FULL ARTICLE at DailyFinance

3 Health-Care Stories You Should Know

By Brandy Betz, The Motley Fool

Filed under:

Heading into this holiday weekend, health-care stocks continue to lead the S&P 500 in 2013. But behind the share-price gains is an industry undergoing dramatic changes. While fellow fool Sean Williams recaps the week’s biotech and pharmaceutical news, here’s a look at the top stories from the other parts of the health-care industry.

Two stories this week displayed the uncertainty that surrounds some forthcoming Obamacare changes. In addition, a Consumer Reports investigation showed which drugstores have the lowest margins on generic drugs.

The Volunteer State and Medicaid
Arkansas’ tentative permission to use federal Medicaid expansion money to purchase private insurance led many other states to pursue that route. But the matter’s a bit more complicated, and Sarah Kliff reports at WonkBlog that Tennessee has run into opposition from the Department of Health and Human Services.

The problem wasn’t the state’s desire to use the money for private insurance, but that Gov. Bill Haslam also proposed that the newly eligible Medicaid members should have similar co-pays to others in the health-insurance exchanges. And that could mean the government might spend far more than it would on a traditional Medicaid plan. The HHS remains open to negotiations, but Gov. Haslam seems firm in his proposal.

Tennessee’s Medicaid program includes Magellan as its pharmacy benefits manager and counts UnitedHealth and WellPoint as its major insurance backers. So investors for those companies should keep an eye on this story.

Medicare cuts
Turning to the Medicare side of the Affordable Care Act, health plans rose this week on the suggestion that Medicare Advantage rates might see lower cuts than previously announced. Those rates were based on the assumption that Congress will go through with a 25% physician pay cut for next year, which would require the higher insurance rates for balance. But Congress hasn’t implemented the pay cut in more than a decade, so the rate cuts haven’t been necessary. We’ll find out for sure with the final rate announcement on Monday. Humana is overly dependent on Medicare, and shares were up nearly 3% on Wednesday following the news.

Finding cheap drugs
Consumer Reports was out with a study showing which drugstores have the best prices on generic medications. Costco had the lowest prices, while CVS Caremark had the highest. The publication theorizes that the price difference comes from how much the pharmacy segment means to the overall business. After all, a big-box store like Costco can afford narrower margins on its generics because there’s more general store than pharmacy, while CVS is more dependent on its pharmacy to drive the bottom line.

The story of our generation?
What macro trend was Warren Buffett referring to when he said “this is the tapeworm that’s eating at American competitiveness”? Find out in our free report: “What’s Really Eating at America’s Competitiveness.” You’ll also discover an idea to profit as companies work to eradicate this efficiency-sucking tapeworm. Just …read more
Source: FULL ARTICLE at DailyFinance

The Best Easter Weekend Deals and Freebies

By Matt Brownell

Peeps on sale

Filed under: , ,

Getty Images

There are plenty of deals and freebies to be had during the Easter weekend. Some retailers are aiming to attract last-minute chocolate egg shoppers; others are just using the holiday as an excuse for a sale. Regardless, here are some of the great buys you can get this weekend.

Bass Pro Shops holds free events every weekend, and FreeStuffTimes alerts us that this weekend is all about Easter. Go to the fishing supply store on Saturday or Sunday and your kids can participate in a free egg hunt, decorate their own bunny magnet, and get a free 4-by-6-inch photo with the Easter Bunny. The events will be happening at most locations, but check the website to make sure your own local shop isn’t excluded.

Sponsored Linksadsonar_placementId=1505951;adsonar_pid=1990767;adsonar_ps=-1;adsonar_zw=242;adsonar_zh=252;adsonar_jv=’ads.tw.adsonar.com’;

When you’re done finding eggs and taking pictures with a man in a giant rabbit suit, why not head to the Outback Steakhouse. Kids eat free on Easter Sunday when you purchase an adult entrée; the terms of the deal note that children 10 and under can get one entrée and drink from the “Joey Menu” for every adult entrée at the table. There’s a limit of four free meals per table.

If you’re like us, you go to the local drugstore for your Easter candy. Walgreens is offering 3 packages of marshmallow peeps for $2. You want to stock up on eggs for an egg-decorating party (or because you just happen to need eggs this weekend), you can get two-dozen store-brand eggs for $2. CVS is offering the same deal on Peeps — Peep price war! — as well as other deals on candy and stuffed rabbits.

Matt Brownell is the consumer and retail reporter for DailyFinance. You can reach him at Matt.Brownell@teamaol.com, and follow him on Twitter at @Brownellorama.

Permalink | Email this | Linking Blogs | Comments

…read more
Source: FULL ARTICLE at DailyFinance

Supreme Court Line Flush With Excitement, Cupcakes, Lollipops, Jay-Z

By The Huffington Post News Editors

WASHINGTON –Twelve hours before the Supreme Court takes up one of the biggest civil rights cases in a generation, Dave Odenbach was handing out lollipops.

“You want a Tootsie Pop?” the Minnesota native asked those who had camped our for days to witness oral arguments in the case that will decide the fate of California’s gay marriage ban. Odenbach, now a D.C. resident, said he couldn’t just sit around as people camped out to hear Hollingsworth v. Perry at 10 a.m. on Tuesday. So he picked up some Tootsie Pops from a CVS in Logan Circle and headed to the Supreme Court building.

“I’m super envious of the people coming in and doing this, and I just thought, I can’t not come down and say hi to the people and cheer them on,” Odenbach told The Huffington Post. “So I just thought I’m coming on down, and I’m bringing Tootsie Pops as a little gift.”

Read More…
More on Prop 8

…read more
Source: FULL ARTICLE at Huffington Post

Walgreen Dreams of Going Global

By Jacob Roche, The Motley Fool

Filed under:

Walgreen  shares soared Tuesday as the company announced higher-than-expected quarterly profits and a new partnership with pharmaceutical distributor AmerisourceBergen and European drugstore Alliance Boots.

For the quarter, net sales were flat, but gross margin improved 120 basis points, leading to a 10.7% increase in net income for the quarter. Notably, net sales were only flat by virtue of opening new stores during the quarter, masking disappointing same-store metrics, which ended up somewhat complicated. Overall same-store sales were down several percentage points, while the average customer ticket went up, but customer traffic went down. So, essentially, customers are spending more, but there are too few customers for it to matter, which isn’t a sustainable situation.

Exciting developments
Walgreen’s sales have been slumping for a year now, though, so that isn’t anything new. The real story is the AmerisourceBergen and Alliance Boots partnership. The partnership will help reduce some of Walgreen’s operational costs, as AmerisourceBergen will begin distributing a number of generic pharmaceuticals that Walgreen traditionally self-distributed. AmerisourceBergen’s superior supply chain will allow for greater efficiencies and daily deliveries.

Alliance Boots and Walgreen have also been granted the option to purchase a significant minority equity position in AmerisourceBergen, through warrants and equity totaling 21% of the company. Once Walgreen and Alliance Boots have together acquired at least 5% of AmerisourceBergen, a Walgreen executive will be placed on the board, and an Alliance Boots executive will be added upon exercise of the warrants.

Alliance Boots is essentially the Walgreen of Europe. Both companies are the largest retail pharmacies in their respective region, putting them in a good position to profit from aging populations that will increasingly need more prescription drugs.

Interestingly, Walgreen purchased 45% of Alliance Boots last summer and has the option to acquire the rest of the company in two years. In that event, Walgreen would have significant influence over AmerisourceBergen. This is part of Walgreen’s plan to create a “global, pharmacy-led, health and well-being enterprise” — an ambitious goal.

Launching the flagship
Barely mentioned Tuesday, but still important, is Walgreen’s flagship strategy. The company is planning three new flagship stores over the next couple of months, in addition to the current four, which offer, among other things, professional manicures, a cafe, a smoothie bar, and a selection of premium cheeses, fresh sushi, and organic food.

Seven stores is hardly enough to move the needle on the company’s declining sales, even if the flagship stores are doing well (Walgreen hasn’t given information specifically about these stores). The stores are also bigger than 20,000 square feet, so even if the concept works, Walgreen can’t just convert its existing stores to the same format. But it may be able to scale the concept down and use the flagship stores to attract attention and brand awareness, a key commodity in the retail market.

Competitors CVS  and Rite Aid  are also revamping their in-store strategies. CVS has added fresh sandwiches and …read more
Source: FULL ARTICLE at DailyFinance